Objective. Recent animal studies suggest that activation of Wnt/β-catenin signaling in articular chondrocytes might be a driving factor in the pathogenesis of osteoarthritis (OA) by stimulating amongst others the expression of matrix metalloproteinases (MMPs). This study aimed to investigate the role of Wnt/β-catenin signaling in IL-1β-induced MMP expression in human chondrocytes.
(Addgene plasmid 10878) (23) . pLKO.1 vectors containing a scrambled shRNA (Addgene plasmid 18640) (24) and an shRNA sequence against human β-catenin (Addgene plasmid 18803) (25) were used. Lentiviral vectors and packaging vectors were transfected into HEK293T cells to produce lentiviruses. Lentiviruses were harvested and used to infect chondrocytes in the presence of 6 µg/ml polybrene (Sigma-Aldrich).
siRNA transfection. Mouse embryonic fibroblasts (MEFs) were transfected with ONTARGETplus SMARTpool siRNA (Thermo Scientific) using the X-tremeGENE siRNA transfection reagent (Roche).
Reporter assay. Human chondrocytes were infected with Cignal™ lentiviruses containing the NF-κB responsive reporter or a TCF/LEF reporter (SA Biosciences) together with lentiviruses constitutively expressing Renilla luciferase (SA Biosciences) in the presence of 6 µg/ml polybrene (Sigma-Aldrich). Luciferase activity was measured using Dual-Glo luciferase assay kit (Promega). Activity of firefly luciferase was normalized for Renilla luciferase activity.
Statistical analysis. Data were expressed as the mean ± SD and analyzed by two-tailed student's t-tests or one-way ANOVA. P-values < 0.05 were considered statistically significant. *, P < 0.05; **, P < 0.01.
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Results
Canonical Wnt signaling inhibits MMP mRNA expression in human chondrocytes.
To investigate the effect of Wnt/β-catenin signaling on MMP expression, human articular chondrocytes isolated from knee joints of OA patients undergoing total knee replacement surgery were treated with recombinant human (rh) Wnt3A or the GSK3 inhibitor BIO. Fig. 1D ) (26, 27) .
We next explored the effect of Wnt/β-catenin signaling on the expression of MMPs and chondrocyte markers. To our surprise activation of canonical Wnt signaling either by Wnt3A or BIO significantly decreased the mRNA expression of MMP1, MMP3 and MMP13 in human chondrocytes (Fig. 1) . In agreement with a recent study, the expression of chondrocyte markers Col2A1 and Sox9 was decreased (Supplemental Fig. 1E ) (27) .
We further explored the effect of Wnt3A on the catabolic gene expression. The decrease in MMP mRNA expression by Wnt3A was dose-dependent and gradual, first measurable 6 hours after the start of treatment with maximum inhibition after 72 hours (Supplemental Fig. 1F&G ). The inhibition could be reversed by DKK-1, which also efficiently blocked 9 Wnt3A-induced expression of the established Wnt target gene Axin2 (Supplemental Fig.   1H&I ). Notably, blocking of endogenous canonical Wnt signaling by DKK-1 slightly, but significantly increased basal transcription levels of MMP1 and -13 mRNA (Supplemental Fig. 1H ). Taken together, these data suggest that Wnt3A represses MMP mRNA expression in human chondrocytes via a signaling cascade downstream of the Frizzled/LRP receptor complex and probably through β-catenin.
In sharp contrast, stimulation of mouse cartilage explants with recombinant mouse (rm) Wnt3A or BIO induced MMP3 and MMP13 mRNA expression ( Fig. 1) , which is in accordance with previously reported data (12). Similarly stimulation of bovine chondrocytes with BIO induced MMP3 and MMP13 expression (Fig. 1 ). The species difference could not be explained by chondrocyte dedifferentiation, an established effect of culturing chondrocytes in monolayer, since direct treatment of human cartilage explants with Wnt3A also reduced MMP mRNA expression (Fig. 1) . To exclude that the observed species difference in the regulation of MMP mRNA expression by canonical Wnt signaling in chondrocytes was due to an OA-induced change in cell response, the experiments were repeated using human chondrocytes from a donor without degenerative cartilage disease and from a donor with RA. Also in cells from these donors, Wnt3A inhibited MMP1, -3 and -13 expression (Fig. 1) . Similar results were obtained using human fetal chondrocytes excluding an age-related effect (Fig. 1) . Finally, activation of canonical Wnt signaling in multipotent human mesenchymal stem cells (hMSCs) which were able to differentiate into chondrocytes also reduced MMP mRNA expression ( Fig.   1 ), suggesting that a decrease in MMP1, -3 and -13 mRNA expression upon activation of canonical Wnt signaling is a conserved response in various human cell types. In 10 conclusion, these data point to a remarkable species difference in regulation of MMP mRNA expression by Wnt/β-catenin signaling in human and animal chondrocytes.
Wnt/β-catenin signaling inhibits IL-1β-induced MMP expression and activity in human chondrocytes. IL-1β is a potent activator of MMP expression in human chondrocytes and has been implicated in cartilage degradation in OA (6) (7) (8) (9) . To test the effect of canonical Wnt signaling on IL-1β-induced MMP1 and -13 mRNA expressions, human chondrocytes were co-stimulated with IL-1β and Wnt3A or BIO. As expected, IL-1β potently induced expression of MMP1 and -13 at the mRNA and proMMP1 and -13 at the protein level ( Fig. 2A) . Co-stimulation with Wnt3A or BIO blocked, while coincubation with DKK-1 further increased IL-1β-induced MMP expression ( Fig. 2A) .
Both Wnt3A and BIO inhibited proMMP1 and -13 protein expression under basal conditions and after co-stimulation with IL-1β (Fig. 2B) . The inhibitory effect of Wnt3A on MMP1 and -13 mRNA and protein expression was associated with a decrease in generic MMP activity secreted in the culture media and in cell extracts. This effect was observed in both basal conditions and after co-treatment with IL-1β (Fig. 2C) . BIO did not decrease generic MMP activity in basal conditions but inhibited IL-1β-induced MMP activity. These data suggest that activation of Wnt/β-catenin signaling in human chondrocytes negatively regulates the expression and activity of a set of MMP family members in both basal conditions and after stimulation by IL-1β.
Crosstalk of Wnt/β-catenin and IL-1β signaling pathways in human chondrocyte.
The potentiating effect of DKK-1 on MMP1-and -13 expression in human chondrocytes in both basal and IL-1β stimulated conditions suggested the presence of endogenous canonical Wnt family members in human chondrocytes repressing MMP expression.
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Using a qPCR survey, we identified relatively abundant mRNA expression of the noncanonical Wnt5A and lower expression levels of the non-canonical Wnt4, -5B, -9A and the canonical Wnt7B (Supplemental Table 2 ). Wnt7B was the only canonical Wnt upregulated by IL-1β. The mRNA expression of Wnt7B peaked at 24hrs after IL-1β stimulation, which coincided with the peak in MMP1 and MMP13 mRNA expression and after which both MMP1 and -13 mRNA and Wnt7B mRNA started to decrease.
Interestingly, IL-1β treatment simultaneously downregulated mRNA expression of several canonical Wnt signaling inhibitors including DKK-1, FRZB and WIF-1 (Fig. 3A ).
DKK1 and WIF1 mRNA expression started to decrease from 4 hours after stimulation and reached the lowest expression levels at 24 hours (Fig. 3A) . The decrease in FRZB mRNA expression was more gradual (Fig. 3A) . As a consequence of the opposite effects on the expression of Wnt7B and its antagonists, β-catenin protein accumulated in both nuclear and cytoplasmic compartments upon stimulation of human chondrocytes with IL-1β ( (7) (8) (9) . This increase in MMP1 mRNA was not reflected in an increase in MMP1 protein expression, which is most likely explained by a lag phase between an increase in mRNA expression and protein expression (Fig. 5A ). MMP3 expression was regulated by both p50 and p65 (Supplemental Fig. 3C ). We next examined the effect of Wnt3A on NF-κB activity, using lentiviral transduction of a NF-κB responsive promoter reporter construct in human chondrocytes. Treatment of Wnt3A significantly decreased basal and IL-1β-induced NF-κB reporter activity (Fig. 5B ). This effect was dependent on β-catenin, since knockdown of β-catenin abolished a Wnt3A-induced decrease in NF-κB promoter reporter activity and enhanced IL-1β-induced reporter activation (Fig. 5B) . Using a coimmunoprecipitation (Co-IP) assay, we found that β-catenin was able to form a protein complex with NF-κB p65 in human chondrocytes under basal condition (Fig. 5C ). The interaction between β-catenin and NF-κB p65 was weakened upon activation of NF-κB by IL-1β and strengthened after Wnt3A induced stabilization of β-catenin. Our data 14 suggest that activation of NF-κB signaling by IL-1β in human chondrocytes may require dissociation of β-catenin from the NF-κB signaling complex. Co-immunoprecipitation of β-catenin with NF-κB p65 was also found in bovine chondrocytes and mouse embryonic fibroblasts (Supplemental Fig. 4A ). Wnt3A was able to decrease basal and IL-1β-induced NF-κB activity in MEFs (Supplemental Fig. 4B ), suggesting that the interaction between β-catenin and NF-κB alone may not explain the species differentiation in the regulation of MMP expression by Wnt/β-catenin signaling.
We next tested whether canonical Wnt signaling could downregulate other NF-κB target genes. We tested this hypothesis by evaluating the effect of Wnt3A treatment on expression of IL-6 and SERPINA1, two established target genes of the NF-κB pathway in human chondrocytes (Supplemental Fig. 3C ). The mRNA expression of both genes was upregulated by IL-1β but downregulated by stimulation with Wnt3A (Fig. 5D ). Wnt3A treatment was also able to decrease IL-1β-induced IL6 mRNA expression but failed to significantly counteract the effect of IL-1β on SERPINA1 mRNA expression (Fig. 5D ).
These results suggest that Wnt/β-catenin signaling negatively regulates a subset of NF-κB target genes most likely via an inhibitory protein-protein interaction with NF-κB. Previous studies have shown that β-catenin inhibits NF-κB-mediated signaling in human cancer cells by a protein-protein interaction between β-catenin and NF-κB (32) (33) (34) . In human chondrocytes, it is well known that activation of NF-κB signaling by proinflammatory cytokines like IL-1β potently induces cartilage matrix degradation by stimulating the expression and activity of various MMPs. We therefore tested whether crosstalk between β-catenin and NF-κB could explain the inhibitory effects of canonical Wnt signaling on MMP expression in human chondrocytes. We extend the observations made in cancer cells to human chondrocytes and show that activated β-catenin signaling can inhibit a number of NF-κB target genes. We furthermore show that activation of NF-κB weakens the protein-protein interaction while stabilization of β-catenin strengthens the interaction between NF-κB and β-catenin. These data strongly suggest that the TCF/LEF-independent repressive effect of β-catenin on MMP expression is mediated by negative cross-regulation of the NF-κB signaling pathway. Remarkably, coimmunoprecipitation assays using mouse embryonic fibroblasts and bovine chondrocytes demonstrate the presence of a protein complex between NF-κB and β-catenin in these cells. In addition, we showed that Wnt3A was able to decrease NF-κB reporter activity in mouse cells. These data suggest that mouse β-catenin was able to inhibit NF-κB-mediated signaling and that this interaction cannot explain the species difference in regulation of MMP expression by canonical Wnt signaling. Our data suggest that in animal cells the canonical Wnt/β-catenin signaling pathway via TCF/LEF prevails over the inhibitory effects on NF-κB signaling in regulation of MMP-3 and -13 expressions in remarkable contrast to human cells in which the non-canonical effect on NF-κB is dominant.
There has been longstanding debate whether animal models are suited for studying the pathogenesis of OA and it is believed that none of the current models can recapitulate all facets of human disease. Our observation of differential regulation of MMP expression by Wnt/β-catenin signaling may explain part of this discrepancy. Although evolutionarily conserved, our data indicate that the Wnt/β-catenin pathway is able to activate distinct subsets of target genes in a species-dependent manner which is at least partly explained by differential usage of canonical and non-canonical β-catenin signaling. We propose that differential usage of crosstalk of signaling networks may be responsible for species differences in cellular responses to Wnt and other extracellular signaling pathways (26, 35) . Our findings suggest that animal models may not be suited for studying the role of Wnt/β-catenin signaling in human OA and questions whether strategies aimed at inhibiting β-catenin in chondrocytes will be successful in the management of OA.
Recently, it has been shown that Wnt3A can modulate the human articular chondrocyte phenotype by activating both β-catenin-dependent and -independent pathways (27) . In line with our study, Nalesso et al. showed that chondrocyte proliferation and inhibition of MMP13 expression is β-catenin-dependent. In contrast, effects of Wnt3A on the expression of chondrocyte markers are β-catenin-independent.
These data are supported by the observation that the non-canonical Wnt5A potently inhibits Col2A1 expression and induces MMP expression (36, 37) . Taken together, these and our data suggest prominent roles for both canonical and non-canonical Wnt signaling In summary, our study unravels an unexpected and novel role of Wnt/β-catenin signaling in human articular chondrocytes with respect of the expression of MMPs (Fig.   6 ). During OA development, β-catenin signaling is upregulated in human cartilage. This A, Human chondrocytes were treated for 48 hours with 10 ng/ml IL-1β or IL-1β in combination with 200 ng/ml rhWnt3A, 1 µM BIO or 300 ng/ml DKK-1. MMP1 and -13 mRNA expression was measured by qPCR. *p<0.05, **p<0.01, n = 3 donors each tested in triplicate. B, Human chondrocytes were treated for 48 hours with 200 ng/ml rhWnt3A, 1 µM BIO and 10 ng/ml IL-1β and proteins were isolated from cell extracts. pro-MMP1 and pro-MMP13 were detected by immunoblot. C, Culture media (left) and cell lysates (right) of human chondrocytes were collected for generic MMP activity measurements after treatment with 200 ng/ml rhWnt3A, 1 µM BIO and 10 ng/ml IL-1β or combinations thereof for 72 hours. *p<0.05, **p<0.01, n = 3 donors each tested in triplicate. C, Protein lysates of human chondrocytes stimulated with 100 ng/ml rhWnt3A, 5 ng/ml IL-1β or both for 48 hours were isolated and subjected to immunoprecitation using NF-κB p65 antibody as bait. Co-immunoprecipitated proteins were detected by immunoblot. D, Human chondrocytes were treated with 200 ng/ml rhWnt3A, 10 ng/ml IL-1β or both for 48 hours. IL6 and SERPINA1 mRNA expression was measured by qPCR. *p<0.05, **p<0.01, N.S. = Not Significant, n = 4 donors each tested in triplicate. (control, CTL) for 48 hours. Mouse cartilage explants (n = triplicate cultures) were treated with 200 ng/ml rmWnt3A or 1 µM BIO for 5 days and bovine chondrocytes (n = triplicate cultures) were treated with 1 µM BIO for 48 hours. Human cartilage explants (n = triplicate cultures from one donor) were treated for 5 days and normal human articular chondocytes, human MSCs, human RA chondrocytes and human fetal chondrocytes (n = triplicate cultures from one donor) were treated for 48 hours with 200 ng/ml rhWnt3A. mRNA expression was measured by qPCR. Data are expressed as mean fold change compared to CTL. *p<0.05, **p<0.01. 114x156mm (300 x 300 DPI) Figure 2 . Wnt/β-catenin signaling reduces IL-1β-induced MMP expression and activity. A, Human chondrocytes were treated for 48 hours with 10 ng/ml IL-1β or IL-1β in combination with 200 ng/ml rhWnt3A, 1 µM BIO or 300 ng/ml DKK-1. MMP1 and -13 mRNA expression was measured by qPCR. *p<0.05, **p<0.01, n = 3 donors each tested in triplicate. B, Human chondrocytes were treated for 48 hours with 200 ng/ml rhWnt3A, 1 µM BIO and 10 ng/ml IL-1β and proteins were isolated from cell extracts. pro-MMP1 and pro-MMP13 were detected by immunoblot. C, Culture media (left) and cell lysates (right) of human chondrocytes were collected for generic MMP activity measurements after treatment with 200 ng/ml rhWnt3A, 1 µM BIO and 10 ng/ml IL-1β or combinations thereof for 72 hours. *p<0.05, **p<0.01, n = 3 donors each tested in triplicate. 126x190mm (300 x 300 DPI) Figure 3 . Crosstalk of Wnt/β-catenin and IL-1β pathways. A, Time course evaluation of mRNA expression after stimulation of human chondrocytes treated with 10 ng/ml IL-1β. mRNA expression of Wnt7B, MMP1 and -13 and the Wnt antagonists DKK1, FRZB and WIF1 was evaluated at indicated time points by qPCR. Data represent the mean fold change relative to non-treated cells which was set to 1. Not statistically significant (4hr: FRZB; 12hr: FRZB), p<0.05 (4hr: MMP1, MMP13, DKK1, WIF1; 72hr: WNT7B, MMP13), p<0.01 (other time points), n = 3 donors each tested in triplicate. B, Human chondrocytes were stimulated with 20 ng/ml IL-1β for 48 hours and nuclear and cytoplasmic β-catenin protein expression was detected by immunoblot. C, Human Wnt3 and Wnt7B were overexpressed using lentiviral transduction in human chondrocytes and MMP mRNA expression was measured by qPCR. Data are expressed using lentiviral GFPtransduced cells as control (Lenti-GFP). D, Wnt7B was knocked down by lentivirus-mediated expression of shRNA in human chondrocytes using scrambled shRNA (shScr) as control. MMP1 and -13 mRNA expression was measured 24 hours after stimulation with 10 ng/ml IL-1β and compared to control (CTL). n = triplicate cultures from one donor (C&D). 82x38mm (300 x 300 DPI) Figure 4 . Effects of β-catenin, TCF4 and LEF1 knockdown. A-C, Human chondrocytes were transduced with lentiviruses expressing scrambled shRNA (shScr) and shRNA (sh) against human β-catenin (shCat) (A&B), TCF4 and LEF1 (C) and treated with 50 ng/ml rhWnt3A for 24 hours. MMP mRNA expression was measured by qPCR and expressed as fold change relative to control (CTL) (A&C) and proteins were detected by immunoblot (B). **p<0.01, n = 3 donors each tested in triplicate. D, MEFs were transfected with negative control siRNA (siNeg) and siRNA (si) against β-catenin (siCat), TCF4 and LEF1, and then treated with or without 200 ng/ml rmWnt3A for 48 hours. MMP13 mRNA expression was measured by qPCR. n = triplicate cultures. 94x50mm (300 x 300 DPI) Figure 5 . β-catenin suppresses MMP expression through an inhibitory interaction with NF-κB. A, MMP mRNA was assessed by qPCR and protein expression was detected by immunoblot in human chondrocytes transduced with lentiviruses expressing scrambled shRNA (shScr) and shRNA against NFKB1 and RELA after treatment with 10 ng/ml IL-1β for 24 hours. qPCR data are expressed as fold change using untreated shScr-transduced cells as control. n = triplicate cultures from one donor. B, Human chondrocytes were transduced with lentiviruses expressing an NF-κB reporter and Renilla lucifease only or together with lentiviruses expressing scrambled shRNA and shRNA against β-catenin. Chondrocytes were treated with 100 ng/ml rhWnt3A, 5 ng/ml IL-1β or both for 24 hours and luciferase reporter activity was measured. Data are expressed as fold change compared to control (CTL). **p<0.01, n = 3 donors each tested in triplicate. C, Protein lysates of human chondrocytes stimulated with 100 ng/ml rhWnt3A, 5 ng/ml IL-1β or both for 48 hours were isolated and subjected to immunoprecitation using NF-κB p65 antibody as bait. Coimmunoprecipitated proteins were detected by immunoblot. D, Human chondrocytes were treated with 200 ng/ml rhWnt3A, 10 ng/ml IL-1β or both for 48 hours. IL6 and SERPINA1 mRNA expression was measured by qPCR. *p<0.05, **p<0.01, N.S. = Not Significant, n = 4 donors each tested in triplicate. 84x39mm (300 x 300 DPI) 
